8-K: Dermata and Revance Collaborate on Clinical Trial for Topical Hyperhidrosis Treatment

Dermata Therapeutics and Revance Therapeutics have entered into a clinical trial collaboration to evaluate a novel topical treatment for excessive underarm sweating using Dermata's Xyngari and Revance's Daxxify.

Summary

• Dermata Therapeutics and Revance Therapeutics have agreed to collaborate on a Phase 2a clinical trial.
• The trial will assess the safety, tolerability, and preliminary efficacy of Dermata's Xyngari combined with Revance's Daxxify for treating moderate-to-severe axillary hyperhidrosis.
• The study will be a randomized, double-blind, placebo-controlled trial involving approximately 48 patients across multiple sites in the United States.
• The trial will last for 16 weeks and will measure the reduction in sweat production using gravimetric methods.
• Dermata will sponsor, conduct, and fund the trial, while both companies will form a joint development committee to oversee the study.
• Revance has granted Dermata a non-exclusive license to use certain intellectual property for the trial, and Dermata has granted Revance a similar license for Xyngari.
• The agreement will terminate upon completion of the trial, data delivery, and statistical analysis.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment due to the collaboration between two companies and the potential for a novel treatment. However, it also acknowledges the inherent risks and uncertainties of clinical trials, preventing a higher score.

Positives

• The collaboration combines Dermata's unique delivery system with Revance's botulinum toxin.
• The trial has the potential to create the first approved needle-free intradermal delivery of a botulinum toxin product.
• The study will evaluate a novel topical treatment option for hyperhidrosis.
• Both companies are contributing their expertise and resources to the trial.
• The trial has a clear structure with defined endpoints and a joint development committee for oversight.

Negatives

• The agreement is limited to a single Phase 2a clinical trial.
• The agreement will terminate upon completion of the trial, data delivery, and statistical analysis.
• The success of the trial is not guaranteed, and results may not lead to future product development or approvals.

Risks

• The clinical trial may not enroll an adequate number of patients on time or be completed on schedule.
• The trial may not generate positive clinical data.
• There are uncertainties inherent in clinical trials, including the risk that past results may not be indicative of future results.
• The development, approval, and commercialization of the product are subject to various risks and uncertainties.
• The companies may not be able to agree on terms for additional clinical trials or a broader partnership.

Future Outlook

The companies may explore clinical development in additional indications if the initial trial is successful, and there is potential for a broader partnership in the future.

Management Comments

• Gerald Proehl, CEO of Dermata, stated that the collaboration will provide a framework to evaluate the treatment effect of Xyngari with Daxxify for hyperhidrosis and potentially other indications.
• Mark Foley, CEO of Revance, expressed excitement about partnering with Dermata to explore the potential of Daxxify and Xyngari for needle-free treatment of hyperhidrosis.

Industry Context

This collaboration reflects a growing trend in the pharmaceutical industry to explore novel delivery methods for existing drugs, particularly in the field of dermatology and aesthetics. The combination of a topical delivery system with a botulinum toxin could offer a less invasive alternative to traditional injections.

Comparison to Industry Standards

• The use of botulinum toxin for hyperhidrosis is a well-established practice, with products like Botox being commonly used via injection.
• The novelty of this collaboration lies in the topical delivery of the botulinum toxin using Dermata's Xyngari technology, which aims to eliminate the need for injections.
• Other companies, such as Allergan (now AbbVie) with Botox, have a strong presence in the botulinum toxin market, but this collaboration is exploring a new delivery method.
• The Phase 2a trial is a standard approach for evaluating the safety and efficacy of a new treatment before moving to larger, more expensive Phase 3 trials.
• The trial design, including the use of a placebo control and multiple endpoints, is consistent with industry best practices for clinical trials.

Stakeholder Impact

• Shareholders of both Dermata and Revance may see a positive impact if the trial is successful.
• Patients with hyperhidrosis may benefit from a new, less invasive treatment option.
• Employees of both companies will be involved in the trial and potential future development.
• The collaboration may lead to new business opportunities for both companies.

Next Steps

• The companies will form a joint development committee.
• Dermata will initiate and conduct the Phase 2a clinical trial.
• The companies will monitor the progress of the trial and analyze the results.
• The companies will explore potential future collaborations and indications based on the trial results.

Key Dates

Keywords

clinical trial, hyperhidrosis, topical treatment, Xyngari, Daxxify, botulinum toxin, Dermata Therapeutics, Revance Therapeutics, axillary hyperhidrosis, needle-free delivery